MAPK3 and familial pancreatic carcinoma: Indeed, the recent study of Azizan et al. showed that RAGE inhibition with the small molecule RAGE inhibitor FPS-ZM1 was sufficient to reduce ERK1/2 activity in tumors from an orthotopic mouse model of pancreatic cancer [65].